NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics
SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry clinics.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.